Aurion Biotech, Inc. (AURN)

Aurion Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	52.07	41.35	18.87
Cash & Cash Equivalents	52.07	41.35	18.87
Cash Growth	-	119.18%	-
Other Current Assets	1.06	0.55	0.39
Total Current Assets	54.57	41.9	19.25
Property, Plant & Equipment	-	3.16	2.49
Goodwill and Intangibles	-	6.49	7.56
Other Long-Term Assets	-	1.06	1.03
Total Long-Term Assets	-	10.71	11.07
Total Assets	-	52.61	30.32
Accounts Payable	-	0.85	1.01
Current Debt	-	1.24	0.98
Other Current Liabilities	14.9	7.14	7.3
Total Current Liabilities	14.9	9.22	9.29
Long-Term Debt	-	5.45	6.73
Total Long-Term Liabilities	-	5.45	6.73
Total Liabilities	-	14.68	16.02
Total Debt	62.55	6.69	7.71
Debt Growth	-	-13.22%	-
Retained Earnings	-	-157.85	-112.3
Comprehensive Income	-	-1.49	-1.43
Shareholders' Equity	-220.54	-176.85	-135.47
Net Cash (Debt)	-10.49	34.66	11.16
Net Cash (Debt) Growth	-	210.65%	-
Working Capital	39.67	32.68	9.96